Clinical trials: Substance Related Disorder
Cannabis, Cannabis Use
Marijuana Effects on Simulated Driving Performance
This study will examine the effects of various strains of marijuana on simulated driving performance; the effects of alcohol administration will also be examined to further understand how marijuana-induced driving changes compare…
- Conditions
- Cannabis, Cannabis Use, Marijuana, Marijuana Usage
- Trial name
- NCT03699540
- Testing
- Marijuana, Alcohol, Inactive marijuana
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Shanna Babalonis, PhD
Opioid Related Disorders, Opioid Dependence
Medications Development for Drug Abuse Disorders
This is a study of tramadol as an agent for short-term opioid withdrawal treatment. A randomized, double blind clinical trial comparing the efficacy and safety of tramadol to clonidine and buprenorphine in the short-term…
- Conditions
- Opioid Related Disorders, Opioid Dependence, Opioid Addiction
- Trial name
- NCT01188421
- Testing
- Buprenorphine/naloxone, Clonidine, Tramadol ER
- Where
- United States
- Volunteers
- 106 people
- Sponsor
- Johns Hopkins University
Substance Use
Telehealth-Clinical Advocacy Project
The purpose of this study is to develop a clinical telehealth intervention and test the feasibility of integrating telehealth within a police opioid county diversion program.
- Trial name
- (T-CAP) (NCT04911426)
- Testing
- Telehealth
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Texas Christian University
Cannabis Dependence
Facilitating the Behavioral Treatment of Cannabis Use Disorder
Cannabis use disorders remain a significant public health problem. The pharmacological facilitation of behavioral treatment represents a promising strategy for addressing disordered cannabis use.
- Trial name
- NCT02946489
- Testing
- CI-581a
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- New York State Psychiatric Institute
Neonatal Abstinence Syndrome
Blinded Trial of Buprenorphine or Morphine in the Treatment of the Neonatal Abstinence Syndrome
The opioid neonatal abstinence syndrome (NAS) is a condition of withdrawal symptoms after utero exposure to opioids. In an open label Phase 1 trial sublingual buprenorphine was associated with a ~30% reduction length of treatment…
- Trial name
- NCT01452789
- Testing
- sublingual buprenorphine, oral morphine
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Thomas Jefferson University
Alcohol Use, Marijuana Use
Motivational Interviewing and Culture for Urban Native American Youth (MICUNAY)
The investigators plan to develop and test a new alcohol and other drug (AOD) intervention for urban AI/AN youth, "Motivational Interviewing and Culture for Urban Native American Youth (MICUNAY)." This intervention integrates…
- Trial name
- MICUNAY (NCT02290938)
- Testing
- MICUNAY, Community Wellness Gathering
- Where
- 2 sites in United States
- Volunteers
- 185 people, healthy volunteers welcome
- Sponsor
- RAND
Drug Use Disorders, Hepatitis C
Community-Based, Client-Centered Prevention Homes to Address the Rural Opioid Epidemic- Aim 3
The goal of this study was to effectively use a client-centered community-based intervention to engage people who inject drugs (PWIDs) in healthcare that helps reduce risky behaviors and lower infectious disease risks.
- Conditions
- Drug Use Disorders, Hepatitis C, Harm Reduction, Opioid-use Disorder
- Trial name
- NCT04268173
- Testing
- Community-Based, Client-Centered Prevention Home
- Where
- 6 sites in United States
- Volunteers
- 343 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Substance Use Disorders, Bipolar Disorder
Treatment With Quetiapine for Youth With Substance Use Disorders and Severe Mood Dysregulation
This study proposes to use quetiapine as an adjunct treatment to treatment as usual to improve both substance use disorder (SUD) and mood symptoms in youth with SUD and severe mood dysregulation (SMD).
- Conditions
- Substance Use Disorders, Bipolar Disorder, Mood Disorders
- Trial name
- NCT02845453
- Testing
- Quetiapine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Boston Medical Center
Amphetamine Dependence
Extended Release Naltrexone for Treating Amphetamine Dependence in Iceland
Until positive results were found with oral naltrexone, no medication has been effective against amphetamine dependence. The primary aim of this pilot study is to replicate the findings of the Swedish team that showed oral…
- Trial name
- NCT01100853
- Where
- Iceland
- Volunteers
- 100 people
- Sponsor
- University of Pennsylvania
Cocaine Use Disorders
D-Cycloserine Facilitation of Cocaine - Cue Extinction
The purpose of this study is to explore the use of d-cycloserine (DCS) to facilitate extinction of response to cocaine cues in cocaine-dependent individuals, in hopes that it may lead to the development of new treatment options…
- Trial name
- NCT00759473
- Testing
- D-Cycloserine (DCS)
- Where
- 2 sites in United States
- Volunteers
- 79 people
- Sponsor
- Medical University of South Carolina
Bipolar Disorder, Anxiety
Quetiapine Extended Release (XR) in Bipolar Patients With Comorbid Generalized Anxiety Disorder (GAD)
The primary objective is to test the hypothesis that Quetiapine XR (Extended Release) monotherapy and adjunctive therapy is effective in the acute treatment of bipolar depression and comorbid generalized anxiety disorder in…
- Conditions
- Bipolar Disorder, Anxiety, Anxiety Disorders, Substance Use Disorders
- Trial name
- NCT00671853
- Testing
- Quetiapine XR
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University Hospitals Cleveland Medical Center
Tobacco Use Disorder
Evaluation of Oral Tobacco as a Harm Reduction Method for Smokers
Recently, tobacco companies have developed new oral tobacco products that are purportedly less harmful than conventional tobacco products.
- Trial name
- NCT00711100
- Testing
- Camel Snus, Marlboro Snus, Stonewall
- Where
- 2 sites in United States
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Cannabis Dependence
Quetiapine Pharmacotherapy for Cannabis Dependence
Despite a benign public perception, marijuana use disorders represent a significant public health problem. The development of safe and effective pharmacotherapies for marijuana dependence is an important unmet public health need.
- Trial name
- QUEST (NCT01697709)
- Testing
- Quetiapine
- Where
- United States
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute
Alcoholism
Seroquel for Frequent, Heavy Drinkers
The purpose of this study is to examine the effects of quetiapine in reducing percent heavy drinking days and increasing percent abstinent days in alcohol dependent patients who are frequent heavy drinkers.
- Trial name
- NCT00674765
- Testing
- Seroquel
- Where
- United States
- Volunteers
- 156 people
- Sponsor
- University of Pennsylvania
Cannabis-use Disorders
Behavioral Effects of Pregabalin and Cannabis
Cannabis is the most commonly used illicit drug in the United States, and its use is associated with rates of development of abuse and dependence, treatment admission and relapse that are comparable to other illicit drugs.
- Trial name
- NCT01511640
- Testing
- Pregabalin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Joshua A. Lile, Ph.D.
HIV/AIDS, Substance Use Disorders
HIV+ Substance Users Released From Jail
The long-term goal of this project is to improve HIV and substance use outcomes and reduce recidivism for HIV+ substance users released from jail.
- Trial name
- NCT03834779
- Testing
- DOORS-CHW Intervention
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Texas Southwestern Medical Center
Schizophrenia, Psychotic Disorders
Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder
The purpose of this study is to compare the efficacy of oral risperidone (Risperdal) to risperidone long-acting (Consta) in reducing alcohol use in persons diagnosed with schizophrenia or schizoaffective disorder.
- Conditions
- Schizophrenia, Psychotic Disorders, Substance Abuse, Alcohol Abuse
- Trial name
- NCT00130923
- Testing
- Risperidone Long Acting, oral risperidone
- Where
- 8 sites in United States
- Volunteers
- 95 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Sleep Disturbance, Opioid-use Disorder
Examining the Role of the Orexin System in Sleep and Stress in Persons With Opioid Use Disorder
This study is designed to elucidate the role of the orexin neurotransmitter system in sleep disturbance and circadian rhythms of stress that might in turn influence relapse behaviors in persons on medication-assisted treatments…
- Trial name
- NCT04287062
- Testing
- Suvorexant
- Where
- 5 sites in United States
- Volunteers
- 249 people
- Sponsor
- Johns Hopkins University
Alcoholism, Alcohol Dependence
Baclofen for Treating Anxiety and Alcoholism
Background: Baclofen is a drug used to control muscle stiffness in people with neurological diseases. Some studies suggest that baclofen may reduce alcohol craving and use.
- Conditions
- Alcoholism, Alcohol Dependence, Alcohol Drinking Related Problems, Alcohol Drinking
- Trial name
- NCT01751386
- Testing
- Baclofen
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Tobacco Use Disorder, Schizophrenia
Nicotine and Sensorimotor Replacement for Smoking in Smokers With Schizophrenia
The objective of this study is to investigate the relative contributions of nicotine replacement and sensorimotor replacement (i.e., smoking denicotinized cigarettes) on abstinence-induced smoking urges, withdrawal-related…
- Trial name
- NCT01213524
- Testing
- sensorimotor replacement, 42 mg transdermal nicotine replacement, usual brand smoking
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Brown University